Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates

Core Insights - Cue Biopharma has appointed Usman "Oz" Azam, M.D., as the new President and CEO effective September 29, 2025, transitioning Daniel Passeri to a Strategic Advisor role [1][5][4] - The leadership change aims to enhance the company's focus on autoimmune diseases, particularly advancing the first-in-class tolerogenic drug candidate CUE-401 [2][5] Leadership Transition - Daniel Passeri emphasized that the transition is a strategic step forward for the company's development, particularly in autoimmune disease [2] - Dr. Azam brings over 25 years of experience in drug discovery and development, having held leadership roles in various biopharmaceutical companies [2][3] - The board of Cue Biopharma expressed confidence in Dr. Azam's ability to drive the company's growth and thanked Passeri for his leadership [3][4] Focus on Autoimmune Disease - Cue Biopharma is prioritizing the development of CUE-401, which is designed to restore immune homeostasis and tolerance, potentially disrupting the standard of care in autoimmune diseases [3][6] - CUE-401 is characterized as a bifunctional molecule that combines a TGF-beta breathing-mask moiety with a clinically validated interleukin (IL-2) mutein [6] Company Overview - Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing a novel class of injectable biologics to engage and modulate disease-specific T cells [5][6] - The company's proprietary platform, Immuno-STAT®, aims to harness the immune system's potential without broad systemic immune modulation [6][7]